Sirolimus for the treatment of multi-resistant pure red cell aplasia |
| |
| Authors: | Huijuan Jiang Huiqin Zhang Yihao Wang Weiwei Qi Qiuying Cao Limin Xing Rong Fu Zonghong Shao Huaquan Wang |
| |
| Affiliation: | Department of Haematology, General Hospital, Tianjin Medical University, Tianjin, China |
| |
| Abstract: | Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies. |
| |
| Keywords: | sirolimus pure red cell aplasia therapy |
|
|
